Evan Kearns J.D. serves as Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary of the Company. Mr. Kearns joined Agenus in 2014 as our Corporate Counsel and became our Associate General Counsel in 2015. Prior to Agenus, Mr. Kearns worked at the law firm Goodwin Procter LLP. Mr. Kearns holds a B.A. in Economics from Colby College and a J.D. degree from the University of Toledo College of Law.
As the Chief Compliance Officer, Vice President, General Counsel a Corporate Secretary of Agenus Inc, the total compensation of Evan Kearns at Agenus Inc is $1,610,580. There are 2 executives at Agenus Inc getting paid more, with Garo Armen having the highest compensation of $9,937,040.
Evan Kearns is 39, he's been the Chief Compliance Officer, Vice President, General Counsel a Corporate Secretary of Agenus Inc since 2018. There are 13 older and no younger executives at Agenus Inc. The oldest executive at Agenus Inc is Wadih Jordan, 85, who is the Independent Director.
Evan's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAK, LEXINGTON, MA, 02421.
Over the last 23 years, insiders at Agenus Inc have traded over $24,466,328 worth of Agenus Inc stock and bought 13,248,226 units worth $63,837,873 . The most active insiders traders include Associates Gp Llcqvt Fund V..., Noubar Afeyan a Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of $2,230,885. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth $325,000.
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Agenus Inc executives and other stock owners filed with the SEC include: